Tools for Practice Outils pour la pratique


#364 Facing the Evidence in Acne, Part II: Oral Antibiotics


CLINICAL QUESTION
QUESTION CLINIQUE
How effective are oral antibiotics in treating acne of at least mild-moderate severity?


BOTTOM LINE
RÉSULTAT FINAL
Approximately 17% of patients achieve “success” on oral minocycline versus 9% on placebo at 12 weeks.  Oral antibiotics reduce acne lesion count by 10-24% more than placebo. Evidence of the efficacy of adding oral antibiotics to topical agents (example: retinoids, benzoyl peroxide) is limited. Efficacy appears similar between individual antibiotics. Discontinuations due to adverse events are comparable to placebo.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Five systematic reviews1-5 (10-25 randomized controlled trials [RCTs], 165-4521 patients) of oral antibiotics (95% tetracyclines), mild to severe acne. After ~12-24 weeks:
    • Total lesion count (percent absolute reduction):
      • Oral antibiotic=10-24% reduction versus placebo1-5 (example: 33% versus 23% [placebo]).4
      • Oral antibiotic + benzoyl peroxide + retinoid (topical)=35-44% reduction versus placebo alone.2,5
      • Oral antibiotics versus topical clindamycin: Not statistically different.2,4
    • Inflammatory lesion count (percent absolute reduction):
      • Oral antibiotic=13-27% reduction versus placebo1-4 (example: 46% versus 33% [placebo]).4
      • Oral antibiotic + benzoyl peroxide + retinoid (topical)=37% reduction versus placebo alone.2
      • Oral antibiotics versus topical clindamycin: Not statistically different.2,4
    • Investigators global assessment of success:4
      • 17% (minocycline) versus 9% (placebo); number needed to treat (NNT)=13.
    • Discontinuation due to adverse events:
      • No difference versus placebo.2,5
        • Exception: One systematic review: minocycline 9% versus 1% placebo (included regimens up to 3 times usual dose).4
  • No difference between different oral antibiotics in terms of efficacy or adverse event discontinuations.3,4
  • Limitations: Patient-assessed outcomes not reported in systematic reviews, inadequate efficacy reporting of adding oral antibiotics to topical agents versus topical agents alone; few RCTs comparing oral antibiotics to topical agents; inadequate data on antimicrobial resistance.

CONTEXT
CONTEXTE
  • Guidelines generally recommend:
    • Adding oral antibiotics to topical treatments for moderate-to-severe acne or acne resistant to topical treatments.6-8
    • ~12-week course of oral antibiotics, then reassessment.6-8 UK guidelines suggest considering a second 12-week course if acne improved but not completely clear.8
  • Topical retinoids and oral tetracyclines contraindicated during pregnancy;8 contraception discussion recommended if of childbearing age.


Ronald Maier April 27, 2024

Adding oral antibiotic in addition to topical treatment likely beneficial for patients

gregory Stroh April 29, 2024

Prefer a far more liberal approach in using roaccutane


Latest Tools for Practice
Derniers outils pour la pratique

#373 Strategies for initiating insulin in type 2 diabetes

What is the optimal initial insulin for patients with type 2 diabetes?
Read Lire 0.25 credits available Crédits disponibles

#372 Mission Slimpossible Part 2: Oral GLP-1 agonists for weight loss

Are oral GLP-1 agonists effective for weight loss?
Read Lire 0.25 credits available Crédits disponibles

#371 It’s time to challenge penicillin allergy labels!

Can low-risk patients with beta-lactam allergy receive an oral beta-lactam challenge safely?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Allison Paige MD CCFP
  • Sasha Katwaroo PharmD candidate
  • Brianne Desrochers PharmD candidate
  • Jamie Falk PharmD

1. Mavranezouli I, Daly CH, Welton NJ, et al. Br J Dermatol. 2022; 187(5):639–49.

2. Huang CY, Chant IJ, Bolick N, et al. Ann Fam Med. 2023; 21(4):358–69.

3. Koo BS, Petersen TD, Kimball AB. J Am Acad Dermatol. 2014; 71(3):450–9.

4. Garner SE, Eady A, Bennett C, et al. Cochrane Database Syst Rev. 2012; 8: CD002086.

5. National Institute for Health and Care Excellence (NICE). Acne vulgaris: management options for moderate to severe acne – network meta-analysis. Available at: https://www.nice.org.uk/guidance/ng198/evidence/f1-management-options-for-moderate-to-severe-acne-network-metaanalyses-pdf-9144159955; Updated June 2021. Accessed December 12, 2023.

6. Zaenglein AL, Pathy AL, Schlosser BJ, et al. J Am Acad Dermatol. 2016; 74:945-73.

7. Asai Y, Baibergenova A, Dutil M, et al. CMAJ. 2016; 188(2):118-126.

8. National Institute for Health and Care Excellence (NICE). Acne vulgaris: management. Available at: https://www.nice.org.uk/guidance/ng198/resources/acne-vulgaris-management-pdf-66142088866501; Accessed December 12, 2023.

Authors do not have any conflicts of interest to declare.